Eli Lilly & Co. is seeking US FDA approval for baricitinib to treat adults with moderate to severe rheumatoid arthritis (RA) who have inadequately responded to or cannot tolerate methotrexate, but members of the agency's Arthritis Advisory Committee suggested on April 23 that the JAK1/2 inhibitor's risk-benefit profile could limit the drug's market.
Multiple advisory committee panelists recommended baricitinib’s indication be limited to moderate to severe RA patients who have failed or can’t...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
